Prevention of prosthetic valve endocarditis by impregnation of gentamicin into surgical pledgets.
A novel drug delivery system was developed for the treatment of prosthetic valve endocarditis (PVE). The antibiotic, gentamicin, was impregnated into surgical pledgets using non-solvent coacervation of polylactic acid (PLA) as a binding/encapsulating agent. The in vitro dissolution profiles show controlled release of gentamicin for up to 36 h when PLA of molecular weight 2000 is used and up to 7 d for PLA with a molecular weight of 50,000. The results indicate potential for the localized treatment of PVE, which is cost-effective, easy to manufacture and permits dosage variability.
Khor
E
E
Department of Chemistry, National University of Singapore, Kent Ridge, Singapore.
Tay
L F
LF
Goh
K S
KS
Lee
C N
CN
D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D004697:Endocarditis, Bacterial / Q000517:prevention & control*; D005839:Gentamicins / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D006350:Heart Valve Prosthesis; D006801:Humans; D008854:Microscopy, Electron; D011183:Postoperative Complications; D011474:Prosthesis Design
D000900:Anti-Bacterial Agents; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D005839:Gentamicins